Switch theme
Sign up to access all valuation multiples
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
2014
131
LTM Revenue $15.0M
LTM EBITDA -$36.9M
$99.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Profound Medical has a last 12-month revenue (LTM) of $15.0M and a last 12-month EBITDA of -$36.9M.
In the most recent fiscal year, Profound Medical achieved revenue of $10.7M and an EBITDA of -$32.1M.
Profound Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Profound Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | XXX | $10.7M | XXX | XXX | XXX |
| Gross Profit | $9.9M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | -$36.9M | XXX | -$32.1M | XXX | XXX | XXX |
| EBITDA Margin | -246% | XXX | -301% | XXX | XXX | XXX |
| EBIT | -$41.2M | XXX | -$33.1M | XXX | XXX | XXX |
| EBIT Margin | -275% | XXX | -310% | XXX | XXX | XXX |
| Net Profit | -$38.8M | XXX | -$27.8M | XXX | XXX | XXX |
| Net Margin | -259% | XXX | -260% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Profound Medical's stock price is $4.
Profound Medical has current market cap of $130M, and EV of $99.8M.
See Profound Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $99.8M | $130M | XXX | XXX | XXX | XXX | $-1.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Profound Medical has market cap of $130M and EV of $99.8M.
Profound Medical's trades at 9.3x EV/Revenue multiple, and -3.1x EV/EBITDA.
Equity research analysts estimate Profound Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Profound Medical has a P/E ratio of -3.4x.
See valuation multiples for Profound Medical and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $130M | XXX | $130M | XXX | XXX | XXX |
| EV (current) | $99.8M | XXX | $99.8M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.4x | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProfound Medical's last 12 month revenue growth is 99%
Profound Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Profound Medical's rule of 40 is -273% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Profound Medical's rule of X is 2% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Profound Medical and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 99% | XXX | 87% | XXX | XXX | XXX |
| EBITDA Margin | -246% | XXX | -301% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -273% | XXX | -202% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 159% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 375% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Profound Medical acquired XXX companies to date.
Last acquisition by Profound Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Profound Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Profound Medical founded? | Profound Medical was founded in 2014. |
| Where is Profound Medical headquartered? | Profound Medical is headquartered in United States of America. |
| How many employees does Profound Medical have? | As of today, Profound Medical has 131 employees. |
| Who is the CEO of Profound Medical? | Profound Medical's CEO is Dr. Arun Menawat,PhD. |
| Is Profound Medical publicy listed? | Yes, Profound Medical is a public company listed on NAS. |
| What is the stock symbol of Profound Medical? | Profound Medical trades under PROF ticker. |
| When did Profound Medical go public? | Profound Medical went public in 2016. |
| Who are competitors of Profound Medical? | Similar companies to Profound Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Profound Medical? | Profound Medical's current market cap is $130M |
| What is the current revenue of Profound Medical? | Profound Medical's last 12 months revenue is $15.0M. |
| What is the current revenue growth of Profound Medical? | Profound Medical revenue growth (NTM/LTM) is 99%. |
| What is the current EV/Revenue multiple of Profound Medical? | Current revenue multiple of Profound Medical is 6.7x. |
| Is Profound Medical profitable? | Yes, Profound Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Profound Medical? | Profound Medical's last 12 months EBITDA is -$36.9M. |
| What is Profound Medical's EBITDA margin? | Profound Medical's last 12 months EBITDA margin is -246%. |
| What is the current EV/EBITDA multiple of Profound Medical? | Current EBITDA multiple of Profound Medical is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
